SINGAPORE, June 1, 2026, 02:13 (SGT)
Cuprina Holdings (Cayman) Limited heads into the new week with its Nasdaq listing still in play after a rough Friday close. The Singapore-based biomedical company’s Class A shares finished at $2.40 on May 29, down 27.27%, the company’s stock page showed.
Why it matters now: Cuprina said Nasdaq staff had determined the company’s securities would be scheduled for delisting after it failed to regain compliance with the $1.00 minimum bid price rule, an exchange requirement tied to the price buyers are willing to pay for a stock. The firm said it filed a hearing request on May 28, which keeps the shares trading while a Nasdaq Hearings Panel reviews the case.
Nasdaq’s regular cash session is closed over the weekend, so Friday’s close is still the latest official mark. U.S. exchange trading normally runs Monday through Friday from 9:30 a.m. to 4:00 p.m. Eastern time, excluding market holidays.
Last week was about listing mechanics. Nasdaq’s corporate-action notice said Cuprina’s one-for-eight reverse split and par value change took effect on May 27, with the CUSIP changed to G2592E110.
A reverse stock split reduces the number of shares outstanding and usually lifts the quoted price, but it does not by itself add cash or change the value of the business. On a split-adjusted basis, meaning older prices are restated for the new share count, Cuprina rose 12.9% on Wednesday and 49.0% on Thursday, then gave back 27.3% on Friday, historical data showed.
Chief Executive David Quek had called the consolidation an “important step” toward “maintaining our Nasdaq listing” when the company announced shareholder approval for the move. GlobeNewswire
The operating backdrop remains small. Cuprina said in its annual report that 2025 revenue was S$49,894, while its net loss widened to S$4.67 million; the filing also listed 10 full-time employees at year-end.
The broader market did not explain Friday’s slide. Wall Street’s main indexes hit record closing highs on May 29, with the Dow up 0.72%, the S&P 500 up 0.22% and the Nasdaq up 0.21%, Reuters reported.
The wound-care angle puts Cuprina near listed advanced wound-care names such as MiMedx and Organogenesis, but the week’s move looked more like a listing issue than a sector trade. MiMedx says its advanced wound products address non-healing acute and chronic wounds, while Organogenesis markets products for chronic and acute wounds; their shares closed Friday at $3.68 and $2.57, respectively.
But the split is not the same as a cure. Nasdaq says a company generally must keep its closing bid price at or above $1.00 for 10 straight business days to regain minimum-bid compliance, and staff can require a longer period in some circumstances.
That leaves the week ahead focused on the panel process, closing bid levels and any company update on compliance. For now, the stock’s trade is simple enough, if uncomfortable: the listing question is leading the story, not the product pipeline.
